LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) has been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $9.8571.
A number of equities research analysts have recently issued reports on LFST shares. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a research note on Thursday, March 12th. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. UBS Group boosted their price target on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research boosted their price target on shares of LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 27th.
View Our Latest Report on LFST
Key LifeStance Health Group News
- Positive Sentiment: JPMorgan raised its price target on LifeStance Health Group to $9.00 from $8.00, while keeping a neutral rating, suggesting modest upside from current levels. JPMorgan raises price target on LifeStance Health Group
- Positive Sentiment: Barclays reiterated a Buy rating on LFST, reinforcing bullish analyst views around the stock. Barclays sticks to its Buy rating for LifeStance Health Group
- Positive Sentiment: Recent coverage also highlighted rising earnings estimates and strong momentum, which can support investor confidence in LFST’s near-term outlook. Earnings estimates rising for LifeStance Health
- Neutral Sentiment: LifeStance Health presented at the Bank of America Global Healthcare Conference, which keeps the company in front of investors but does not appear to be a major fresh catalyst on its own. LifeStance Health presents at Bank of America Global Healthcare Conference
- Negative Sentiment: Directors Darren M. Black, Eric Shuey, and Robert Bessler collectively sold millions of shares at $8.02, which may pressure sentiment because insider selling can be viewed as a lack of conviction at current prices. Insider sale filing for Darren M. Black
Insider Activity
In other news, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the sale, the director directly owned 23,310,115 shares of the company’s stock, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Bessler sold 575,034 shares of LifeStance Health Group stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $4,611,772.68. Following the completion of the transaction, the director owned 986,931 shares of the company’s stock, valued at $7,915,186.62. This trade represents a 36.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 11,182,996 shares of company stock valued at $85,295,948. Company insiders own 3.20% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its holdings in shares of LifeStance Health Group by 92.5% in the first quarter. Renaissance Technologies LLC now owns 800,500 shares of the company’s stock valued at $5,099,000 after purchasing an additional 384,600 shares in the last quarter. Sei Investments Co. grew its holdings in shares of LifeStance Health Group by 39.1% in the first quarter. Sei Investments Co. now owns 711,589 shares of the company’s stock valued at $4,533,000 after purchasing an additional 200,041 shares in the last quarter. Militia Capital Management LLC acquired a new position in shares of LifeStance Health Group in the first quarter valued at approximately $1,067,000. First Trust Advisors LP grew its holdings in shares of LifeStance Health Group by 127.0% in the first quarter. First Trust Advisors LP now owns 1,066,191 shares of the company’s stock valued at $6,792,000 after purchasing an additional 596,501 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after purchasing an additional 7,987 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.
LifeStance Health Group Price Performance
Shares of LFST stock opened at $7.89 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.65. The firm’s 50-day moving average is $6.87 and its two-hundred day moving average is $6.78. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.89. The company has a market capitalization of $3.06 billion, a PE ratio of 131.50 and a beta of 1.20.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company had revenue of $403.48 million for the quarter, compared to the consensus estimate of $387.46 million. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. Analysts predict that LifeStance Health Group will post 0.11 earnings per share for the current year.
LifeStance Health Group announced that its board has initiated a share repurchase plan on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.
LifeStance Health Group Company Profile
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Further Reading
- Five stocks we like better than LifeStance Health Group
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
